Martin Oft

Menlo School — United States

Medicine · Health Sciences

31h-index6.9kcitations121works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(57), Immunotherapy and Immune Responses(44), CAR-T cell therapy research(39), Immune Cell Function and Interaction(20), Cancer Research and Treatments(16)

Publications120 total

An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy
Cell Reports·2025Open Access
682 STK-012, a first-in-class α/β IL-2 receptor biased partial agonist enhances the anti-tumor efficacy of bispecific antibodies
Regular and Young Investigator Award Abstracts·2025Open Access
1345 Initial phase 1a/1b results of STK-012, an α/β IL-2 receptor biased partial agonist, with pembrolizumab, pemetrexed, and carboplatin in 1L PD-L1 negative non-squamous NSCLC
2025Open Access
Structure-Guided Stapling of Dimeric Conformations and Linker Engineering Enhance Thermostability and Fine-Tune Activity of Bispecific VHH Cytokine Agonists
Antibodies·2025· 1 citedOpen Access
1709-P: Novel Interleukin-22 Partial Agonists Improve Metabolic Syndrome In Vivo
Diabetes·2025
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
Blood·2024· 5 citedOpen Access
964 Gradual lymphocyte activation with IL-12 partial agonist STK-026 maintains anti-tumor efficacy but escapes acute NK-mediated cytokine release and toxicities associated with WT IL-12
Regular and Young Investigator Award Abstracts·2024Open Access
1325 T cell and immune activation from a phase 1 study of STK-012, a first-in-class IL-2R α/β selective partial agonist in advanced solid tumors
Regular and Young Investigator Award Abstracts·2024Open Access
941 STK-026, a detoxified IL-12 partial agonist is well-tolerated and sustains CD8+ T cell activity with repeat doses in cynomolgus macaques
Regular and Young Investigator Award Abstracts·2024Open Access
IL-2 based cancer immunotherapies: an evolving paradigm
Frontiers in Immunology·2024· 49 citedOpen Access
Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
Cancer Research·2024· 8 cited
Abstract 6312: Orthogonal IL-2/IL-2Rβ signaling selectively enhances and sustains a synthetic effector state via a novel mechanism and outperforms constitutive armoring approaches
Cancer Research·2024
1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
228 Engineered human IL-2/IL-2Rß orthogonal pairs selectively enhance anti-GPC3 CAR T cells in vivo to drive complete responses in solid epithelial tumor models
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory  CD19 expressing hematologic malignancies (NCT05665062)
Cancer Research·2023· 3 cited
Abstract 1833: Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity
Cancer Research·2023
Abstract 1801: STK-012, an a/b-selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity
Cancer Research·2023· 1 cited
Supplementary Table 2 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
Supplementary Table 1 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
Supplementary Table 2 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Aung Naing(12), Jeffrey R. Infante(12), Karen A. Autio(12), Shubham Pant(12), Peter Van Vlasselaer(12), John B. Mumm(11), Kyriakos P. Papadopoulos(11), Manish R. Patel(10), Gerald S. Falchook(9), Ivan H. Chan(8), Johanna C. Bendell(8), Annie Hung(7), Todd M. Bauer(7), Jan Emmerich(6), Deborah J. Wong(6), Scott McCauley(6), Raid Aljumaily(6), Milind Javle(6), Deborah Jean Lee Wong(6), Navneet Ratti(5)